Sanofi/Regeneron’s biologic sarilumab was found superior to AbbVie’s Humira in a Phase III trial. The trial compared the efficacy of the two drugs in improving the signs and symptoms of rheumatoid arthritis (RA) for patients in whom treatment with methotrexate was either inadequate or not tolerated. The study is significant because it marks the first time that an IL-6 receptor blocker delivered subcutaneously has showed superiority over Humira monotherapy in RA.

Click here for more.